louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00000112: Prevalence of Carbohydrate Intolerance in Lean and Obese Children
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Obesity
Glucose Intolerance
Diabetes
Acanthosis Nigricans
Lead sponsor: National Center for Research Resources (NCRR)
Sponsor class: NIH
First posted: 2000-01-19
Sex: ALL
Minimum age (years): 8
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: DEFINED_POPULATION
Time perspective: OTHER

Brief summary: The prevalence of obesity in children is reaching epidemic proportions. Excess adiposity is more than just a cosmetic problem, having substantial metabolic consequences. Insulin resistance, hyperinsulinemia, impaired glucose tolerance, and frank diabetes are often seen in obese children. In this study the prevalence of impaired glucose (carbohydrate) tolerance in lean children with a family history of diabetes and obese children with acanthosis nigricans with or without a family history of diabetes mellitus will be studied.


Eligibility criteria: Inclusion Criteria:

* Obesity: BM +/- 95% for age general good health

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Yale University School of Medicine, Pediatric Endocrinology
state: Connecticut
Study officials:
References:
citation: Halloun R, Galderisi A, Caprio S, Weiss R. Lack of Evidence for a Causal Role of Hyperinsulinemia in the Progression of Obesity in Children and Adolescents: A Longitudinal Study. Diabetes Care. 2022 Jun 2;45(6):1400-1407. doi: 10.2337/dc21-2210.
citation: Ricke J, Klumpen HJ, Amthauer H, Bargellini I, Bartenstein P, de Toni EN, Gasbarrini A, Pech M, Peck-Radosavljevic M, Popovic P, Rosmorduc O, Schott E, Seidensticker M, Verslype C, Sangro B, Malfertheiner P. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019 Dec;71(6):1164-1174. doi: 10.1016/j.jhep.2019.08.006. Epub 2019 Aug 14.
Clinical trial NCT01408212: Effectiveness of Additional Acupuncture Therapy for Lung Cancer Patients
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Lung Cancer
Lead sponsor: Korean Medicine Hospital of Pusan National University
Sponsor class: OTHER
Collaborators: name: Pusan National University Yangsan Hospital
First posted: 2011-08-03
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study aims for evaluating the effectiveness, safety and feasibility of additional acupuncture therapy for lung cancer patients who are under chemotherapy in an inpatient setting. The acupuncture therapy will be administered during a resting period between cycles of chemotherapy.


Eligibility criteria: Inclusion Criteria:

* At least 18 years of age
* Karnofsky Performance Status (KPS) 60% or more
* Undergoing antineoplastic chemotherapy for lung cancer
* Able to provide informed consent

Exclusion Criteria:

* Brain metastasis, stroke or major psychiatric diseases
* Active infection
* Severe heart disease
* Serious systemic diseases such as uncontrolled hypertension and diabetes mellitus
* Acupuncture therapy within the previous three months
* Communication disorder
* Unwillingness to participate in the trial
* Severe immunocompromised state (absolute neutrophils count \< 1000/cubic mm)

Primary outcomes:
measure: Change score of Functional Assessment of Cancer Therapy-Lung (FACT-L) scale from baseline
timeFrame: 7-10 days during a rest period between chemotherapy cycles
Secondary outcomes:
measure: Change score of Functional Assessment of Cancer Therapy-Lung (FACT-L) scale from baseline
timeFrame: 4-5 weeks from baseline (3-4 weeks after treatment termination)
measure: Change score of Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT fatigue) Scale from baseline
timeFrame: Baseline, 7-10 days after baseline, 4-5 weeks after baseline
measure: Change of general condition assessment using visual analogue scale from baseline
timeFrame: Baseline, 7-10 days after baseline, 4-5 weeks after baseline
measure: Adverse events
timeFrame: From study enrollment to the last follow-up (a maximum of day 36)
Other outcomes:
Locations:
city: Yangsan
country: Korea, Republic of
facility: Pusan National University Yangsan Hospital and Korean Medicine Hospital of Pusan National University
state: Gyeongsangnam-do
Study officials:
affiliation: Pusan National University Yangsan Hospital
name: Yun Seong Kim, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Korean Medicine Hospital of Pusan National University
name: Jun-Yong Choi, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00174512: A Methodological Open Label Cross-Over Controlled Study To Assess The Effect Of Drugs On Ventricular Repolarization and QT Interval At Fixed Heart Rate Under Autonomic Blockade
Official title: A Methodological Open-Label Cross-Over Controlled Study To Assess The Effect Of Drugs On Ventricular Repolarisation and QT Interval At Fixed Heart Rate Under Autonomic Blockade
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Patients With Pace Makers But no Evidence of Ischemic Heart Disease
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2005-09-15
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: ECT

Brief summary: To assess the effects of GTN on QT and QTc in subjects with And without atrial pacing. This will be done with and without autonomic blockade at two different pacing rates. Moxifloxacin effect on QT and QTc will also be assessed in atrially paced patients at two different pacing rates with and without autonomic blockade


Eligibility criteria: Inclusion Criteria:

* Patients with pace-makers but otherwise normal ventricular function

Exclusion Criteria:

* Nitrates, beta blockers

Primary outcomes:
measure: QT and QTc changes at two different pacing rates in atrially paced patients
Secondary outcomes:
measure: Change in QT and QTcF before and after Moxifloxacin with and without autonomic blockade at each pacing rate Change in QT and QTcF before and after autonomic blockade at each pacing rate
Other outcomes:
Locations:
city: Bruxelles (Brussels)
country: Belgium
facility: Pfizer Investigational Site
city: Glasgow
country: United Kingdom
facility: Pfizer Investigational Site
state: Scotland
city: Leicester
country: United Kingdom
facility: Pfizer Investigational Site
city: Liverpool
country: United Kingdom
facility: Pfizer Investigational Site
city: London
country: United Kingdom
facility: Pfizer Investigational Site
city: Manchester
country: United Kingdom
facility: Pfizer Investigational Site
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT05472012: Performance of Masimo INVSENSOR00057 in Detecting Atrial Fibrillation (Afib)
Official title: Performance of Masimo INVSENSOR00057 in Detecting Atrial Fibrillation (Afib)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Atrial Fibrillation
Lead sponsor: Masimo Corporation
Sponsor class: INDUSTRY
First posted: 2022-07-25
Enrollment: 139
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This study is designed to validate the performance of Masimo INVSENSOR00057 in detecting atrial fibrillation. The noninvasive ECG measurements will be compared to results obtained from an FDA-cleared ECG monitor.


Eligibility criteria: Inclusion Criteria:

* Subject is 18 years of age or older.
* Subject is confirmed to have active atrial fibrillation at the time of enrollment.

Exclusion Criteria:

* Subject is confirmed to have concurrent active arrhythmias (e.g., PVCs, bradycardia, etc.) at the time of enrollment.
* Subject is allergic to adhesives or ECG gel.
* Subject whose skin is not intact in or at the vicinity of the device placement site.

Primary outcomes:
measure: Sensitivity of INVSENSOR00057 Atrial Fibrillation (Afib) Detection Function
timeFrame: 1-5 hours
measure: Specificity of INVSENSOR00057 Atrial Fibrillation (Afib) Detection Function
timeFrame: 1-5 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Jackson
country: United States
facility: Site 1
state: Tennessee
Study officials:
References:
Clinical trial NCT02692612: Effects of Power-velocity Muscle Characteristics During Ageing
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sarcopenia
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
First posted: 2016-02-26
Enrollment: 98
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: young (20-40y) middle-aged (40-60y) old (60-80y)

Brief summary: The purpose of this project is to investigate the age-related differences in force-velocity muscle characteristics during isolated knee extensions variable in speed and load, during cyclic movements on a usual and recumbent bike variable in speed and velocity development and a functional test battery with healthy participants aged between 20-80 years.


Eligibility criteria: Inclusion Criteria:

* healthy volunteers age 20 to 80 years

Exclusion Criteria:

* Knee or hip prothesis
* Systematic training
* Cardiovascular disease
* Acute lower back pain
* Acute knee pain
* Dementia

Primary outcomes:
measure: Differences in power-velocity characteristics during ageing
timeFrame: 1x at baseline (cross sectional study)
Secondary outcomes:
measure: Reliability of strength tests on regular and recumbent bike.
timeFrame: 1x at baseline (cross sectional study)
measure: Differences in muscle fascicle characteristics during ageing.
timeFrame: 1x at baseline (cross sectional study)
measure: Differences in muscle activation during ageing.
timeFrame: 1x at baseline (cross sectional study)
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: Faculty of kinesiology and rehabilitation sciences
Study officials:
References:
Clinical trial NCT01460212: Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder
Official title: Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Major Depressive Disorder
Keywords: Cognitive-Behavior Therapy
Magnetic Resonance Imaging
major depressive disorder
Lead sponsor: Nanjing Medical University
Sponsor class: OTHER
First posted: 2011-10-26
Enrollment: 80
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Study hypothesis: psychotherapy and SSRI treatment effect in different brain way: psychotherapy in "up to down" way and SSRI in "down to up" way. The investigators will explore this hypothesis in major depressive disorder outpatients with Magnetic Resonance Imaging analysis in this study. Patients in different groups will be treated by psychotherapy or SSRI treatment. They will all be checked with Magnetic Resonance Imaging pro and after 12 weeks of treatment.

Detailed description: Patients meeting the inclusion criteria undergo an examination that included a diagnostic interview, vision test, and psychophysiological measures. Participants then undergo the baseline fMRI scan within 48 hours, after that, they will receive psychotherapy or SSRI treatment.and returned the scan once they completed the therapy.

Eligibility criteria: Inclusion Criteria:

* meet SCID -Ⅰ/P major depressive disorder diagnosis;
* Right handedness;
* good visual acuity.

Exclusion Criteria:

* neurological disease ;
* serious physical illness (e.g. heart, lung, liver, kidney or blood system disease);
* with other mental disorder;
* psychotic symptoms
* personality disorders;
* pregnancy;
* suicidal risk;
* treatment by antidepressants or other psychotropic medications within 6 months prior to the start of the trial;
* with contraindication for MRI

Primary outcomes:
measure: Hamilton Rating Scale for Depression (HAMD)
timeFrame: an expected average of 6 months
Secondary outcomes:
measure: Magnetic Resonance Imaging
timeFrame: an expected average of 6 months
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Nanjing Brain Hospital
state: Jiangsu
Study officials:
affiliation: Nanjing Medical University
name: Chun Wang, doctor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03407612: Outcomes of CPM Usage Following Arthroscopic Acetabular Labral Repair
Official title: The Effect of Continuous Passive Motion on Pain Control Following Hip Arthroscopy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Femoro Acetabular Impingement
Pain, Postoperative
Hip Labral Tear
Keywords: continuous passive motion device
HOS-ADL
hip arthroscopy
Lead sponsor: Ohio State University
Sponsor class: OTHER
First posted: 2018-01-23
Enrollment: 54
Sex: ALL
Minimum age (years): 14
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to measure whether CPM (continuous passive motion) usage improves outcomes following arthroscopic hip surgery that includes labral repair. Investigators tested the hypothesis that CPM usage reduces pain levels and pain medication use and improves function in individuals who undergo hip arthroscopy.

Detailed description: Subjects undergoing primary hip arthroscopy for acetabular labral repair were randomized to determine whether they would receive a CPM. Those subjects receiving a CPM were instructed to use it for 4-6 hours daily throughout the first two postoperative weeks. The total number of pain medications and average pain scores over the two weeks, as well as Hip Outcome Score Activity of Daily Living (HOS ADL) scores at standard time points were compared via a two sample t-test and intention-to-treat analysis.

Eligibility criteria: Inclusion Criteria:

* undergoing hip arthroscopy to repair a torn labrum

Exclusion Criteria:

* pregnancy
* revision surgery
* bilateral surgery

Primary outcomes:
measure: Change in Patient Satisfaction and Functional Outcome
timeFrame: Baseline and 6 weeks, 12 weeks, and 6 months postoperatively
Secondary outcomes:
measure: Analgesic Usage
timeFrame: Initial two postoperative weeks
measure: Pain Level
timeFrame: Initial two postoperative weeks
Other outcomes:
Locations:
city: Columbus
country: United States
facility: The Ohio State University Wexner Medical Center
state: Ohio
Study officials:
affiliation: Ohio State University
name: John Ryan, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04498312: Extracorporeal Shock Wave Therapy Versus Manual Lymphatic Drainageon Cellulite Post Liposuction
Official title: Comparison of Extracorporeal Shock Wave Therapy Versus Manual Lymphatic Drainage on Cellulite Post Liposuction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cellulite
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2020-08-04
Enrollment: 30
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To determine whether extracorporeal shock wave therapy (ESWT) or manual lymphatic drainage (MLD) is more effective for decreasing post-liposuction cellulite.

Thirty females with grade 3 cellulite were randomly distributed into two equal groups: group A (ESWT group) (n=15) and group B (MLD group) (n=15). The cellulite grade was assessed by using the cellulite grading scale, and the thickness of subcutaneous fat was assessed by the skinfold caliper. The assessment was carried out before starting the treatment and after 4 weeks. All participants received treatment 2 times/ week for 4 weeks.


Eligibility criteria: Inclusion Criteria:

* Female patients
* age ranged from 25-45 years old,
* non- pregnant females
* grade 3 cellulite at thigh area after liposuction

Exclusion Criteria:

* Breastfeeding females
* Inflammatory skin disorders in the treatment area
* Edema
* Varicose veins-
* Any therapy or disease that may affect treatment

Primary outcomes:
measure: Cellulite grade
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Marwa Eid
Study officials:
References:
Clinical trial NCT06721312: Continuous Heart Rate Variability Monitoring in Doctors; Understanding Patterns of Stress and Recovery and Their Relationship With Self-reported Resilience, Burnout and Wellbeing.
Official title: Continuous Heart Rate Variability Monitoring in Doctors; Understanding Patterns of Stress and Recovery and Their Relationship With Self-reported Resilience, Burnout and Wellbeing.
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Burnout
Burnout Syndrome
Occupational Stress
Stress
Keywords: Heart rate variability
HRV
occupational stress
resilience
fatigue
wellbeing
stress
burnout
Lead sponsor: University of Aberdeen
Sponsor class: OTHER
First posted: 2024-12-06
Enrollment: 60
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Medical Doctors working within NHS Grampian

Brief summary: Burnout is an increasing concern in the medical professions. This study aims to utilise established, validated self-report measures combined with continuous heart rate variability measurements to better understand the stress and recovery patterns experienced by doctors that may contribute to burnout.

This mixed methods study design will consist of an ecological momentary assessment phase where participants will complete commonly used and validated real-time subjective measures while concurrently wearing a heart rate variability monitor to provide an objective measure of stress. Following on from this, participants of interest will be invited to participate in semi structured interviews to further explore their experiences of stress and recovery.


Eligibility criteria: Inclusion Criteria:

* Working within NHS Grampian
* Access to a smartphone

Exclusion Criteria:

* Cardiac arrhythmias/endocrine disease.
* Prescription beta blockers, calcium channel blockers, ACE inhibitors, benzodiazepines, antidepressants and antianxiety medications.
* Insufficient non-working time prior to study commencement.

Primary outcomes:
measure: Heart rate variability
timeFrame: 7 days
Secondary outcomes:
measure: Burnout
timeFrame: Measured on day 1
measure: Resilience
timeFrame: Measured on day 1
measure: Wellbeing
timeFrame: Measured on day 1
measure: EMA Measures
timeFrame: 8 times/day for 7 days
Other outcomes:
Locations:
city: Aberdeen
country: United Kingdom
facility: NHS Grampian
Study officials:
References:
Clinical trial NCT01512212: New Thyroid Fine Needle Aspiration Biopsy Apparatus
Official title: New Thyroid Fine Needle Biopsy Apparatus
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Thyroid Cancer
Keywords: thyroid
fine
needle
aspiration
biopsy
new
technique
Lead sponsor: SB Istanbul Education and Research Hospital
Sponsor class: OTHER
Collaborators: name: Bezmialem Vakif University
First posted: 2012-01-19
Enrollment: 40
Sex: ALL
Minimum age (years): 17
Maximum age (years): 85
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Evaluation of the effectivity of the new thyroid fine needle aspiration biopsy (FNAB) apparatus of which patented from Turkish Patent Institute.

Detailed description: The author group of this investigation produced a new thyroid fine needle aspiration biopsy (FNAB) apparatus and patented it from Turkish patent Institute. FNAB indicated nodular goitre patients are the subjects of this research. First, the investigators will perform standart FNAB after this procedure will perform FNAB with new apparatus. The investigators will evaluate the aspirates according to number of cells and malignity ratio of cells.

Eligibility criteria: Inclusion Criteria:

* fine needle aspiration biopsy indicated noduler goiter patients

Exclusion Criteria:

* diffuse goiter

Primary outcomes:
measure: number of cells
timeFrame: 2
Secondary outcomes:
measure: type of cells
timeFrame: 2
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Bezmialem Vakif University
state: Marmara
Study officials:
affiliation: Bezmialem Vakif University
name: adnan yuksel, prof
role: STUDY_CHAIR
References:
Clinical trial NCT02414412: Immunity Improvement Effect of Ulmus Macrocarpa Water Extract in Adults
Official title: Immunity Improvement Effect of Ulmus Macrocarpa Water Extract in Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Healthy
Keywords: Ulmus macrocarpa water extract
immunity
Lead sponsor: Pusan National University Hospital
Sponsor class: OTHER
Collaborators: name: Bio Port Korea Inc.
First posted: 2015-04-10
Enrollment: 58
Sex: ALL
Minimum age (years): 19
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This randomized, placebo-controlled, double-blind study evaluates the efficacy and tolerability of Ulmus macrocarpa water extract for immunity improvement in relatively healthy adults. 58 subjects received 500 mg of Ulmus macrocarpa water extract per day or a placebo for 4 weeks.


Eligibility criteria: Inclusion Criteria:

* subject has peripheral white blood cells between 4,000/Ul and 8,000/Ul

Exclusion Criteria:

* History of renal disease
* History of diabetes mellitus
* History of immune disease

Primary outcomes:
measure: serum natural killer cell activity
timeFrame: 1 month
Secondary outcomes:
measure: peripheral white blood cell
timeFrame: 1 month
measure: serum tumor necrosis factor-alpha level
timeFrame: 1 month
measure: serum interferon-gamma
timeFrame: 1 month
measure: serum interleukins(1betta, 2,4,8,10, and 12)
timeFrame: 1 month
Other outcomes:
Locations:
Study officials:
References:
citation: Cho AR, Lee SY, Cho YH, Kim CM, Kim SG. Effects of 4-Week Intervention with Ulmus macrocarpa Hance Extract on Immune Function Biomarkers in Healthy Adults: A Randomized Controlled Trial. Evid Based Complement Alternat Med. 2018 Feb 25;2018:5690816. doi: 10.1155/2018/5690816. eCollection 2018.